COMP <GO>
XENE vs TNGX // OPERATING MARGIN
Xenon Pharmaceuticals Inc. (NASDAQ) VS. Tango Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: XENE 3
— TNGX 6
▲ OPERATING MARGIN LEADER: XENE
LAST: $37.62 (+0.56%) • MKT CAP: $3.62B
operating-margins
-36.70%
LAST: $21.76 (-4.22%) • MKT CAP: $3.83B
operating-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XENE VS. TNGX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XENE | TNGX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -28.90% | -6.10 | TNGX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.70% | -3.68% | -4.02 | TNGX | /fcf-yield <GO> |
| Operating Margin ACTIVE | -36.70% | -60.00% | +23.30 | XENE | /operating-margins <GO> |
| Net Profit Margin | -34.00% | -60.00% | +26.00 | XENE | /net-margins <GO> |
| Revenue Growth (YoY) | 7.70% | 48.30% | -40.60 | TNGX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 26.00 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.3 | 46.9 | -2.60 | TNGX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.87 | +0.23 | XENE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.0x | 28.0x | +1.00 | TNGX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.62B | $3.83B | -$208.0M | TNGX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XENE REV | TNGX REV | XENE GROSS % | TNGX GROSS % | XENE FCF | TNGX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.04B | $62.4M | — | — | -$279.9M | -$139.9M |
| FY 2024 | $782.0M | $42.1M | — | — | -$184.5M | -$132.3M |
| FY 2023 | $599.4M | $36.5M | — | — | -$151.1M | -$119.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XENE // BETA 1.10
TNGX // BETA 0.87